Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
6 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients(Dove Press Ltd., 2018); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A SINGLE INSTITUTIONAL EXPERIENCE WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER(Sestre milosrdnice University Hospital Center University Hospital for Tumors, Zagreb, Croatia, 2022-05); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, POSTOPERATIVE ADJUVANT INTENSITY-MODULATED RADIOTHERAPY FOR RADICALLY RESECTED RECTAL ADENOCARCINOMA: DATA FROM EVERYDAY PRACTICE(Faculty of Medicine, University Ss. Cyril and Methodius in Skopje, 2022-05-04); ; ; Introduction: Adjuvant radiochemotherapy is a standard treatment in patients with surgically treated stage II or III rectal adenocarcinoma who did not undergo neoadjuvant radiotherapy. Intensity-modulated radiation therapy (IMRT) was only marginally investigated in postoperative setting. Material and methods: A longitudinal observational analysis was conducted in patients with radically resected stage II or III rectal adenocarcinoma treated with IMRT at the University Clinic for Radiotherapy and Oncology as part of the adjuvant postoperative treatment. The dose-volume parameters of the radiotherapy plans, as well as acute side effects of 40 patients were analyzed. Results: The average dose received by the target volume was 49.95 Gy (range 27-54 Gy). The mean volume of peritoneal cavity receiving 45 Gy (V45) was 102.73 cm3 (±52.10), V30 for pelvic bones was 38.3% (±5.48), V40 for bladder 52.48% (±10.9). The most frequent acute side effects were diarrhea in 17 (42.5%), lymphopenia in 34 (85%) and thrombocytopenia in 26 patients (65%). Most of the side effects were self-limiting and caused disruption of the radiation treatment only in 3 patients (7.5%). Conclusion: Integrating IMRT in the adjuvant treatment of locally advanced rectal cancer provides a good dose distribution and organs at risk sparing. The treatment is well tolerated, the side effects are mainly of lesser degrees and easily managed. A prospective trial comparing IMRT with 3-dimensional conformal radiotherapy is needed to assess whether IMRT offers a better perspective for adjuvant treatment. Keywords: rectal adenocarcinoma, adjuvant treatment, remove adjuvant treatment, intensity-modulated radiotherapy, acute side effects - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Serum chromogranin-A levels in neuroendocrine neoplasms as prognostic marker in correlation with the clinical course of the disease and the influence of octreotid therapy(Faculty of Medicine, University Ss. Cyril and Methodius in Skopje, 2021-05); ; ; ; Introduction. Neuroendocrine neplasms (NEN) arise from neuroedocrine cells in various tissues and organs, have diverse biological behavior and express neuroendocrine markers synaptophysin and chromogranin A (CgA). Aim of the study. The aim of this study was to correlate the serum CgA levels before and after surgical and/or oncological treatment with octreotide and to determine the prognostic value of CgA variations during the follow-up. Material and methods. We used ELISA to analyze 699 serum samples from 410 patients during 9 years, due to carcinoid syndrome, benign neuroendocrine tumor (NET), localized neuroendocrine carcinoma (NEC) and patients with metastatic NEC (MS). Data from hospital databases were used for follow-up of 60 patients, divided into responders and non-responders, regarding their response to therapy. Results. The mean serum CgA value in 410 analyzed patients was by 3.47-fold increase compared to the maximal reference values. The highest increase was measured in patients with NEC/MS, with mean 12.94-fold increase, followed by patients with localized NECs, with mean 4.57. During follow-up, CgA values were reduced, with a significant difference between the groups of responders and non-responders. Conclusions. Reduction of the CgA level for at least 49.5% during the first 12 months after therapy was correlated with stable disease course, and serum CgA elevation or decrease less than 34% during the first 12 months after the therapy was correlated to unfavorable clinical course. Serum CgA levels are useful for the diagnosis of NENs and during the follow-up for detection of recurrence, disease progression and evaluation of the oncologic therapy response. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association of Systemic Inflammatory Response Syndrome with Bacteremia in Patients with Sepsis(Macedonian Academy of Sciences and Arts/Sciendo, 2019-10-01); ; ; ; The aim of this study was to evaluate the usability of systemic inflammatory response syndrome (SIRS) and commonly used biochemical parameters as predictors for positive blood culture in patients with sepsis. The study included 313 patients aged ≥18 years with severe sepsis and septic shock consecutively admitted in the Intensive Care Unit (ICU) of the University Clinic for Infectious Diseases in Skopje, Republic of North Macedonia. The study took place from January 1, 2011 to December 31, 2017. We recorded demographic variables, common laboratory tests, SIRS parameters, site of infection, comorbidities and Sequential Organ Failure Assessment (SOFA) score. Blood cultures were positive in 65 (20.8%) patients with sepsis. Gram-positive bacteria were isolated from 35 (53.8%) patients. From the evaluated variables in this study, only the presence of four SIRS parameters was associated with bacteremia, finding that will help to predict bacteremia and initiate early appropriate therapy in septic patients. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Determining the Efficiency of a Commercial Belly Board Device in Reducing Small Bowel Volume in Rectal Cancer Patients(Association for Medical Physics and Biomedical Engineering, 2010-11-06);